Metformin Acutely Mitigates Oxidative Stress in Human Atrial Tissue: A Pilot Study in Overweight Non-Diabetic Cardiac Patients

• Published in: Life (Basel, Switzerland) Switzerland), 2022-12, Vol.12 (12), p.2058
• Main Authors: Lascu, Ana, Ionică, Loredana-Nicoleta, Merce, Adrian-Petru, Dănilă, Maria-Daniela, Petrescu, Lucian, Sturza, Adrian, Muntean, Danina-Mirela, Streian, Caius Glad
• Format: Article
• Language: English
• Subjects: Aldosterone; Angiotensin; Angiotensin II; atrial tissue; Body weight; Cardiac patients; Confocal microscopy; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes therapy; Diabetics; Dosage and administration; Drug therapy; echocardiographic parameters; Ejection fraction; Glucose; Health aspects; Heart; Heart atrium; Heart failure; Hydrogen peroxide; Hyperglycemia; Laboratories; Lipopolysaccharides; Metformin; Microscopy; non-diabetic overweight cardiac patients; Overweight; Overweight persons; Oxidants; Oxidation; Oxidative stress; Oxidizing agents; Patients; Peroxides; Reactive oxygen species; Renin; Software; Spectrophotometry; Superoxide; Superoxide anions; Surgery; Testing; Type 2 diabetes
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life12122058

Metformin, the first-line drug in type 2 diabetes mellitus, elicits cardiovascular protection also in obese patients via pleiotropic effects, among which the anti-oxidant is one of the most investigated. The aim of the present study was to assess whether metformin can acutely mitigate oxidative stress in atrial tissue harvested from overweight non-diabetic patients. Right atrial appendage samples were harvested during open-heart surgery and used for the evaluation of reactive oxygen species (ROS) production by means of confocal microscopy (superoxide anion) and spectrophotometry (hydrogen peroxide). Experiments were performed after acute incubation with metformin (10 µM) in the presence vs. absence of angiotensin II (AII, 100 nM), lipopolysaccharide (LPS, 1 μg/mL), and high glucose (Gluc, 400 mg/dL). Stimulation with AII, LPS, and high Gluc increased ROS production. The magnitude of oxidative stress correlated with several echocardiographic parameters. Metformin applied in the lowest therapeutic concentration (10 µM) was able to decrease ROS generation in stimulated but also non-stimulated atrial samples. In conclusion, in a pilot group of overweight non-diabetic cardiac patients, acute incubation with metformin at a clinically relevant dose alleviated oxidative stress both in basal conditions and conditions that mimicked the activation of the renin-angiotensin-aldosterone system, acute inflammation, and uncontrolled hyperglycemia.